Supply Obligations; Alnylam’s Existing Manufacturing Arrangements Sample Clauses

Supply Obligations; Alnylam’s Existing Manufacturing Arrangements. (a) Subject to Section 6.2, from and after the Effective Date, Alnylam will use Diligent Efforts, either itself or through Third Parties, to Manufacture, in accordance with applicable cGMP (as defined in the Supply Agreement Term Sheet), and supply to Cubist API Bulk Drug Substance and Finished Product (as applicable) in quantities that are reasonably sufficient for the conduct of Development and Commercialization by Cubist with respect to the *Confidential Treatment Requested. Omitted portions filed separately with the Commission. Profit-Share Territory under the Development Plan and Commercialization Plan, respectively, and for Development and Commercialization in the Royalty Territory. Cubist shall pay Alnylam an amount equal to Alnylam’s Cost of Goods Sold for API Bulk Drug Substance and Finished Product (as applicable) supplied by Alnylam to Cubist pursuant to this Section 6.1 with respect to the Development and Commercialization in the Royalty Territory, payable within []* after receipt of an invoice therefor in accordance with the Supply Agreement. Alnylam’s Cost of Goods Sold for API Bulk Drug Substance and Finished Product (as applicable) supplied by Alnylam to Cubist pursuant to this Section 6.1 for Development in the Profit-Share Territory shall be included as Development Costs. Alnylam’s Cost of Goods Sold for API Bulk Drug Substance and Finished Product (as applicable) supplied by Alnylam to Cubist pursuant to this Section 6.1 for Commercialization in the Profit-Share Territory shall be shared by the Parties through the calculation of N.A. Pre-Tax Profit or Loss.
Sample 1
AutoNDA by SimpleDocs

Related to Supply Obligations; Alnylam’s Existing Manufacturing Arrangements

  • Supply Agreements For a period of three years from the consummation of the IPO, Odetics shall not unilaterally terminate or assign its guarantee obligation with respect to any supply agreement pursuant to which it has guaranteed the performance by ATL of ATL's obligations, unless such suppliers have consented to the termination or assignment of such guarantee.

  • Manufacturing Agreement Each of the Sellers (as applicable) shall have executed and delivered to the Buyer the Manufacturing Agreement with respect to the portion of the Business conducted at the applicable Facility.

  • Supply Agreement Buyer shall have executed and delivered the Supply Agreement to the Company.

  • Sublicense Agreements Sublicenses shall be granted only pursuant to written agreements, which shall be subject and subordinate to the terms and conditions of this Agreement. Such Sublicense agreements shall contain, among other things, provisions to the following effect:

  • Manufacturing and Supply Genentech shall be responsible for manufacturing and supplying Licensed Products for clinical use and commercial sale in the Genentech Field.

  • Manufacturing Rights Manufacturing Rights will be governed by Attachment 6.

  • Quality Agreement Each Party will comply with the terms of the Quality Agreement in the performance of its obligations hereunder including record retention, audits and inspections, change control, adverse events and product recall. The Parties will conduct periodic Product quality reviews in accordance with the terms of the Quality Agreement.

  • License Agreements (a) Each Borrower and Guarantor shall (i) promptly and faithfully observe and perform all of the material terms, covenants, conditions and provisions of the material License Agreements to which it is a party to be observed and performed by it, at the times set forth therein, if any, (ii) not do, permit, suffer or refrain from doing anything that could reasonably be expected to result in a default under or breach of any of the terms of any material License Agreement, (iii) not cancel, surrender, modify, amend, waive or release any material License Agreement in any material respect or any term, provision or right of the licensee thereunder in any material respect, or consent to or permit to occur any of the foregoing; except, that, subject to Section 9.19(b) below, such Borrower or Guarantor may cancel, surrender or release any material License Agreement in the ordinary course of the business of such Borrower or Guarantor; provided, that, such Borrower or Guarantor (as the case may be) shall give Agent not less than thirty (30) days prior written notice of its intention to so cancel, surrender and release any such material License Agreement, (iv) give Agent prompt written notice of any material License Agreement entered into by such Borrower or Guarantor after the date hereof, together with a true, correct and complete copy thereof and such other information with respect thereto as Agent may request, (v) give Agent prompt written notice of any material breach of any obligation, or any default, by any party under any material License Agreement, and deliver to Agent (promptly upon the receipt thereof by such Borrower or Guarantor in the case of a notice to such Borrower or Guarantor and concurrently with the sending thereof in the case of a notice from such Borrower or Guarantor) a copy of each notice of default and every other notice and other communication received or delivered by such Borrower or Guarantor in connection with any material License Agreement which relates to the right of such Borrower or Guarantor to continue to use the property subject to such License Agreement, and (vi) furnish to Agent, promptly upon the request of Agent, such information and evidence as Agent may reasonably require from time to time concerning the observance, performance and compliance by such Borrower or Guarantor or the other party or parties thereto with the material terms, covenants or provisions of any material License Agreement.

  • Third Party Agreements Nothing in this Section 5.3 shall require any Party to violate any Contract or arrangement with any Third Party regarding the confidentiality of confidential and proprietary information relating to that Third Party or its business; provided, however, that in the event that a Party is required under this Section 5.3 to disclose any such information, such Party shall use commercially reasonable efforts to seek to obtain such Third Party’s consent to the disclosure of such information. The Parties also acknowledge that the Other Parties’ Auditors are subject to contractual, legal, professional and regulatory requirements which such auditors are responsible for complying with.

  • Manufacturing License Subject to the terms of this Agreement, including without limitation Section 2.2, Theravance grants to GSK an exclusive license under the Theravance Patents and Theravance Know-How to make and have made API Compound or formulated Alliance Product in the Territory.

Time is Money Join Law Insider Premium to draft better contracts faster.